<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070837</url>
  </required_header>
  <id_info>
    <org_study_id>M59102-051</org_study_id>
    <nct_id>NCT00070837</nct_id>
    <nct_alias>NCT00074347</nct_alias>
  </id_info>
  <brief_title>MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer</brief_title>
  <official_title>A Phase 1/2 Dose Escalation Trial of Multiple Doses of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen-Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the highest dose of MLN2704 that can be given&#xD;
      multiple times safely to patients with prostate cancer, and to identify any side effects&#xD;
      associated with taking the drug. This study will also evaluate how MLN2704 is taken up,&#xD;
      broken down and eliminated by the body.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date>October 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>46</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN2704 (DM1 conjugated monoclonal antibody MLN591)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic or cytologic diagnosis (recent or remote) of prostate adenocarcinoma&#xD;
&#xD;
          -  Radiographic evidence (recent or remote) of metastatic prostate adenocarcinoma&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Progressive prostate cancer as defined by the presence of one or more of the following&#xD;
             despite castrate levels of testosterone (testosterone &lt;50 ng/dL):&#xD;
&#xD;
               1. Progressive tumor lesions (changes in the size of lymph nodes or parenchymal&#xD;
                  masses on physical examination or X-ray and CT scan or MRI)&#xD;
&#xD;
               2. Progressive bone metastasis (presence of new lesion(s) on a bone scan)&#xD;
&#xD;
               3. Progressive PSA levels (as defined in Section 3.6.1)&#xD;
&#xD;
          -  Subjects who have received an anti-androgen must have shown progression of disease&#xD;
             following discontinuation of the anti-androgen&#xD;
&#xD;
          -  Subjects must remain on luteinizing hormone-releasing hormone (LHRH) analog therapy&#xD;
             for the duration of the trial unless surgically castrate&#xD;
&#xD;
          -  Agree to use an effective barrier method of contraception.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Testosterone &gt;50 ng/dL&#xD;
&#xD;
          -  Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of dosing&#xD;
&#xD;
          -  Use of PC-SPES within 4 weeks of dosing&#xD;
&#xD;
          -  Prior cytotoxic chemotherapy and/or radiation therapy within 6 weeks of dosing&#xD;
&#xD;
          -  Use of anti-androgen therapy (eg, flutamide, bicalutamide, nilutamide) within 6 weeks&#xD;
             of dosing&#xD;
&#xD;
          -  Prior monoclonal antibody administration, including ProstascintÂ®&#xD;
&#xD;
          -  Peripheral neuropathy of &gt; Grade 2, as defined by the NCI Common Toxicity Criteria for&#xD;
             Adverse Events (NCI CTCAE)&#xD;
&#xD;
          -  History of CNS metastasis, including incompletely treated epidural disease&#xD;
&#xD;
          -  History of Hepatitis B or C&#xD;
&#xD;
          -  History of seizure disorder requiring active treatment and/or stroke&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Platelet count &lt;100,000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;1,500/mm3&#xD;
&#xD;
          -  Hematocrit &lt;27 percent&#xD;
&#xD;
          -  Abnormal coagulation profile (elevated PT, and/or INR, PTT)&#xD;
&#xD;
          -  Serum creatinine &gt;2.0 mg/dL, or creatinine clearance &lt;60 mL/min if serum creatinine&#xD;
             &gt;2.0 mg/dL&#xD;
&#xD;
          -  AST or ALT &gt;1.5 x ULN&#xD;
&#xD;
          -  Bilirubin (total) &gt;1.25 x ULN&#xD;
&#xD;
          -  Serum calcium &gt;12.5 mg/dL&#xD;
&#xD;
          -  Active serious infection not controlled by antibiotics&#xD;
&#xD;
          -  Active angina pectoris or NY Heart Association Class III-IV heart disease&#xD;
&#xD;
          -  Karnofsky Performance Status &lt;60%&#xD;
&#xD;
          -  Life expectancy &lt;6 months&#xD;
&#xD;
          -  Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or&#xD;
             hematological organ systems that might preclude completion of this study or interfere&#xD;
             with determination of causality of any adverse effects experienced in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University/ New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Box 3532</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>October 8, 2003</study_first_submitted>
  <study_first_submitted_qc>October 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2003</study_first_posted>
  <last_update_submitted>July 12, 2007</last_update_submitted>
  <last_update_submitted_qc>July 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

